BioSpace News Archive

T2 Biosystems, Inc. announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 2,025,317 shares of common stock, series A warrants to purchase up to 2,025,317 shares of common stock and short-term series B warrants to purchase up to 2,025,317 shares of common stock at a purchase price of $3.95 per share of common stock and accompanying warrants priced at-the-market under Nasdaq rules.

Viracta Therapeutics, Inc. announced that, in connection with the appointment of Michael Faerm as Viracta’s new Chief Financial Officer, Viracta’s Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta’s 2021 Inducement Equity Incentive Plan.

TransMedics Group, Inc. announced that on May 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 18,320 shares of its common stock and an aggregate of 12,068 restricted stock units to 8 employees, each as a material inducement for each employee’s entry into employment with TransMedics.

Acadia Pharmaceuticals Inc. announced that on May 15, 2024, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units to twenty-two new employees under Acadia’s 2023 Inducement Plan.

Personalis, Inc. announced that the Compensation Committee of its Board of Directors granted, on May 15, 2024, a non-qualified stock option to purchase an aggregate of 85,000 shares of its common stock to Personalis’ new Vice President, Customer Experience under Personalis’ 2020 Inducement Plan.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 102,150 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 58,370 shares of common stock and inducement restricted stock units, covering an aggregate of 43,780 shares of its common stock.

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced late-breaking results from the pivotal phase of the admIRE pivotal clinical trial, plus additional results from the VIRTUE study, presented at the Heart Rhythm Society (HRS) Annual Meeting in Boston from May 16-19.

DBV Technologies announced plans to change the ratio of its American Depositary Shares to its ordinary shares, nominal value €0.10 per share, from the current ADS Ratio of one ADS to one-half of one ordinary share to a new ADS Ratio of one ADS to one ordinary share.

BriaCell Therapeutics Corp. announced it has closed its previously announced registered direct offering with healthcare-focused institutional investors and a certain existing investor and a director of the Company for the purchase and sale of 2,402,935 common shares of the Company and warrants to purchase up to an aggregate of 2,402,935 common shares of the Company for aggregate gross proceeds of approximately $5.0 million before deducting placement agent fees and other offering expenses.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its participation in the Infusion Nurses Society Annual Meeting and Exhibition, to be held in Kansas City, Missouri from Saturday, May 18 to Monday, May 20, 2024.